

- A¹ 19. (Amended) The drug carrier of Claim 17, wherein said polyacetal is selected from the group consisting of poly(hydroxymethylethylene hydroxymethylformal).

- A² 34. (Amended) A drug-carrier, comprising:
a) a single-stranded nucleotide; and
b) at least two polymers associated with said single-stranded nucleotide.

Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (page -i-).

REMARKS

The remainder of this amendment is set forth under appropriate subheadings for the convenience of the Examiner.

Information Disclosure Statements

Applicant hereby brings to the attention of the Examiner that PTO Form 1449 associated with a Supplemental Information Disclosure Statement filed on April 12, 2001, including references AB-AF was not returned by the Examiner in the most recent Office Action. The Office Action included Forms PTO 1449 associated only with an Information Disclosure Statement filed on October 16, 2000 and a Second Supplemental Information Disclosure Statement filed on August 9, 2001. For the Examiner's convenience, a copy of the postcard receipt for the Supplemental Information Disclosure Statement, indicating that it was received in the United States Patent and Trademark Office on April 17, 2001, and a copy of the Second Information Disclosure Statement with references is enclosed with this amendment.

Also, Applicant specifically brings to the Examiner's attention a Third Supplemental Information Disclosure Statement, including references AV6-AZ6 and AR7-AW7, which was filed on February 20, 2003, after issuance of the outstanding Office Action, Paper No. 14.

Applicant respectfully requests consideration of the references cited in both the Supplemental Information Disclosure Statement filed on April 12, 2001, and the Third Supplemental Information Disclosure Statement filed on February 20, 2003.